Thomas J. Tucker

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Thomas J. Tucker, Mark W. Embrey, Candice Alleyne et al. · Journal of Medicinal Chemistry · 2021 · 152 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

Douglas G. Johns, Louis‐Charles Campeau, Puja Banka et al. · Circulation · 2023 · 141 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of 3-{5-[(6-Amino-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency against Key Mutant Viruses

Thomas J. Tucker, John T. Sisko, Robert M. Tynebor et al. · Journal of Medicinal Chemistry · 2008 · 133 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design

Candice Alleyne, Rupesh P. Amin, Bhavana Bhatt et al. · Journal of Medicinal Chemistry · 2020 · 128 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Design and Synthesis of a Series of Potent and Orally Bioavailable Noncovalent Thrombin Inhibitors That Utilize Nonbasic Groups in the P1 Position

Thomas J. Tucker, Stephen F. Brady, William C. Lumma et al. · Journal of Medicinal Chemistry · 1998 · 105 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17